Connect with us

Technology

Ovation.io and PD Theranostics (PDTx) Complete Merger Creating a Multiomic Data Company Which Owns a Unique Population-Scale Biobank of Disease-Specific Biospecimens

Published

on

Ovation owns a unique population-scale biobank of consented and linkable disease-specific biospecimens, which includes more than 1.6 million samples from over 600,000 United States-based patients; approximately one-third are tissue samples. Ovation plans to continue expanding the biobank with the addition of 200,000 + patient samples per monthOvation’s biobank includes tissue, blood, and other sample types from patients with diseases of current discovery and development interest including inflammatory bowel disease (IBD), liver disease, chronic kidney disease (CKD), cardio-metabolic/GLP-1, various types of cancers, and neurodegenerative diseases such as Alzheimer’s diseaseThe Company plans to produce a database of linked omics and patient/clinical data for each diseaseThe merger combines teams with deep domain expertise in human genetics, disease pathogenesis, and pathology

PORTLAND, Maine and BOSTON, Sept. 5, 2024 /PRNewswire/ — Ovation.io and PDTx today announced the completion of their merger. The new entity creates an industry-leading multiomics data company managed by a team with deep expertise in genomics data, sequencing, bioinformatics, cell biology, and imaging, AI/ML and data commercialization. The Company’s enhanced platform capabilities and data libraries can drive deeper insights into cellular biology and gene expression for research, drug development, and clinical decision-making, and across a broad range of diseases.

“We believe the two companies are deeply complementary and will provide our customers with best-in-class, diverse multiomics data,” said Curt Medeiros, CEO of Ovation. “These one-of-a-kind data sets will combine Ovation’s DNA and RNA sequencing of patient samples in a given disease state with PDTx’s mapping of cellular footprints, spatial context, immune system functionality and markers, as well as clinical pathology imaging. This will help drive our client’s R&D efforts, from target and biomarker discovery, through optimized clinical trial enrollment.”

Human genomic data has become an increasingly important tool in disease target and biomarker discovery. By analyzing an individual’s genetic makeup, especially in relation to clinical progression and outcomes, researchers are able to better understand the underlying causes of diseases and identify potential therapeutic targets and biomarkers. Ovation is building the world’s broadest commercially available human genomic dataset that brings together whole genome sequences with longitudinal clinical records at the patient level (“clinic-genomics data”) to address the speed and cost at which new research efforts can be powered by human genomics. This clinic-genomics database will enable a depth and breadth of analytics not currently possible due to the scale, continuous flow of new patient samples, and diversity of patients.

“The Ovation and PDTx teams are energized and have been collaborating for the past year to position our first proof-of-concept programs in IBD and prostate cancer for groundbreaking results,” said Patrick Gallagher, CEO of PDTx. “The in-house biobank will allow the team to accelerate data generation and more fully leverage the PDTx platform’s high dimensional, multiomic modalities that characterize cellular status. This includes changes in and predictiveness of proteins, glycans, metabolites and cell-cell spatial relationships that can drive discovery and correlations with pathological features of disease severity, progression and therapeutic response.”

PDTx has developed a disease-agnostic platform to analyze data collected across multiple high-dimensional imaging technologies to discover new drug development targets and identify critical biomarkers of disease progression and therapeutic response. The PDTx platform provides the ability to visualize the presence, concentration, and distribution of molecules and analyze intra- and inter-molecular and phenotypic single-cell relationships and their impact on morphology. Ovation will retain PDTx’s exclusive global license for the platform and its intellectual property from Massachusetts General Hospital (MGH) and the Vaccine and Immunotherapy Center (VIC) at (MGH).

“Ovation’s ability to continuously scale its biobank and data to expand its curated disease cohorts that are representative of racial and geographic diversity in the United States is completely novel,” noted Mike Self, co-founder of StageDotO Ventures. “Linking this with longitudinal patient data creates a totally unique product that will allow for more targeted and efficient investment in development programs for our clients.”

By combining imaging and sequencing, state-of-the-art multiomics can map the location of specific proteins and chemical products in tissues and identify the location of presence of these chemical entities. This provides a critical perspective about the cellular microenvironment and inter-cellular interactions in biopsies of diseased tissue.

“We are incredibly excited to collaborate with the research team at Ovation,” said Mark Poznansky, M.D., Ph.D, director of the Vaccine and Immunotherapy Center at Massachusetts General Hospital. ” Connecting genetic data with cellular, structural and chemical details of tissue affected by IBD or prostate cancer can lead to important translational medical progress. For example, our combining a multiomics platform that provides information on both the genetic and protein signature in blood as well the location of specific chemicals and cells within a tissue, can help identify new sets of biomarkers that are potentially impactful diagnostically and prognostically as well as revealing of new disease related therapeutic targets.”  

About Ovation
Ovation is an omics data company committed to accelerating the development of precision medicine. Ovation provides life sciences R&D teams access to high-quality omics data linked to rich, longitudinal clinical data, across therapeutic areas, at population scale. Ovation’s data increases the probability of success for drug discovery by enabling the identification and validation of biomarkers and therapeutic targets. The company has an extensive biobank of more than 1.6 million geographically diverse, consented biospecimens from over 625,000 unique patients. For more information, visit www.ovation.io or follow the company on LinkedIn.

About PD Theranostics
PDTx is a data driven healthcare company focused on leveraging proprietary workflows and using multi parameter imaging-based methodologies to generate robust, one-of-a-kind multi-omic cellular biology based databases for numerous disease states. Our proprietary imaging processes, driven by a multi-omics approach, will generate spatial roadmaps of human cancers and other diseases, leading to unparalleled data richness and depth. Through our ability to map tissue structures and immune populations, we believe we could more clearly define disease stage, and likelihood of disease progression, and identify the most efficacious treatment regimens for each patient.

Contact Information
Info@ovation.io

Forward-Looking Statement
This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements that relate to the advancement and development of the Ovation Platform and other information that is not historical information. When used herein, words such as “anticipate”, “being”, “will”, “plan”, “may”, “continue”, and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based on Ovation’s current expectations and various assumptions. Ovation believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Ovation may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, market conditions. Consequently, forward-looking statements should be regarded solely as Ovation’s current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. Ovation cannot guarantee future results, events, levels of activity, performance or achievements. Ovation does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.

View original content to download multimedia:https://www.prnewswire.com/news-releases/ovationio-and-pd-theranostics-pdtx-complete-merger-creating-a-multiomic-data-company-which-owns-a-unique-population-scale-biobank-of-disease-specific-biospecimens-302239632.html

SOURCE Ovation.io

Continue Reading

Technology

Legrand Launches Starline T5 DoubleBar, the Highest Ampacity Open-Channel Track Busway with Most Pluggable Space

Published

on

By

WEST HARTFORD, Conn., Oct. 20, 2026 /PRNewswire/ — Legrand, the global specialist in electrical and digital building infrastructures, today launched the Starline T5 DoubleBar track busway. Engineered specifically for high-density environments, the T5 DoubleBar offers the highest ampacity open-channel busway available on the market with the most pluggable space, addressing the exponential power demands of artificial intelligence and high-performance computing.

By featuring a configuration with two T5 bars in parallel, the system delivers up to 2000A, enabling robust power distribution for high-density environments. This hybrid busway design successfully combines open-channel flexibility with busduct-level ampacity for maximum adaptability.

“As AI workloads push rack densities past 100kW, data center operators have been forced into a clear trade-off: install heavy, rigid busducts to get high amperage, or use track busways to maintain operational flexibility,” said Mark Swift, Vice President of Engineering for Starline, a brand of Legrand. “With the T5 DoubleBar, we’ve completely eliminated that compromise. By delivering 2000A in a continuous open-channel architecture, we give operators the raw power density of a traditional busduct without forcing them to clutter their white space with redundant  busway runs or sacrifice the agility to reconfigure on the fly.”

Key Features and Benefits of the Starline T5 DoubleBar

The T5 DoubleBar eliminates spacing constraints common in traditional busduct systems and minimizes the whitespace footprint in dense data center layouts.

Unmatched AI & HPC Support: The system handles rack loads up to 150kW, meeting next-gen data center demands. It is also compatible with LVDC installations to 1000VDC.Increased Pluggable Space: The high-density double-bar architecture utilizes parallel conductors to increase amperage and pluggable space without increasing the system’s footprint.Zero-Downtime Reconfiguration: Hot-pluggable tap-off capability allows for the safe, live installation and removal of tap-off units without a system shutdown, maximizing operational continuity.True Modularity and Scalability: The modular design supports multiple ratings without system redesign. Furthermore, it is designed for future expansion up to 5000A, protecting long-term capital investments.Complete T5 Ecosystem Compatibility: The system maintains open-channel plug-in access and full compatibility with all existing T5 plug-in units.

Launching Alongside High-Capacity Plug-in Unit (HCP)

To complete this end-to-end high-density power distribution system, Legrand is simultaneously launching a new High-Capacity Plug-in Unit (HCP) designed for seamless integration directly on T5 infrastructure, including the new DoubleBar.

These new plug-in units offer up to 250A capacity and multiple enclosure formats, delivering more power through a single unit. By powering high-density AI and HPC racks directly, the HCP reduces the need for multiple lower-amperage plug-ins, simplifying the overall power delivery architecture.

For more information on the Starline T5 DoubleBar and High-Capacity Plug-in Units, visit the Starline website.

About Legrand:

Legrand is the global specialist in electrical and digital building infrastructures. Its comprehensive offering of solutions for residential, commercial, and datacenter markets makes it a benchmark for customers worldwide. The Group harnesses technological and societal trends with lasting impacts on buildings with the purpose of improving life by transforming the spaces where people live, work and meet with electrical, digital infrastructures and connected solutions that are simple, innovative and sustainable. Drawing on an approach that involves all teams and stakeholders, Legrand is pursuing a strategy of profitable and responsible growth driven by acquisitions and innovation, with a steady flow of new offerings that include products with enhanced value in use. Legrand reported sales of €9.5 billion in 2025. The company is listed on Euronext Paris and is a component stock of the CAC 40, CAC 40 ESG and CAC Transition Climat indexes (code ISIN FR0010307819). www.legrand.us

Media Contact:

Jaymie Scotto & Associates
+1 866.695.3629 ext. 19
jsa_legrand@jsa.net

View original content to download multimedia:https://www.prnewswire.com/news-releases/legrand-launches-starline-t5-doublebar-the-highest-ampacity-open-channel-track-busway-with-most-pluggable-space-302914273.html

SOURCE Legrand DPC LLC

Continue Reading

Technology

Trinity Acquires Verix, Adding AI-Powered Next-Best-Action and Omnichannel Orchestration to the TrinityEDGE Platform

Published

on

By

Verix’s patented Tovana™ platform and its full team join Trinity, extending TrinityEDGE™ from what commercial teams know into what they do next

WALTHAM, Mass., Oct. 20, 2026 /PRNewswire/ — Trinity, the leader in integrating human and artificial intelligence for life sciences commercialization, today announced it has acquired Verix, the pharma-native commercial intelligence company behind the patented, AI-powered Tovana™ platform. Tovana is live today in global pharma, biotech, and specialty pharma commercial organizations, where it turns prescription, claims, clinical, and engagement data into continuous next-best-action, dynamic targeting, and omnichannel orchestration for brand, field, and digital teams. The acquisition brings Verix’s entire team into Trinity and adds an AI execution layer to TrinityEDGE. Terms were not disclosed.

Why now

Pharma has already bought AI but has not yet realized the pay off. Trinity’s 2025 Commercial and Medical IT benchmark found that 100 percent of surveyed organizations had adopted generative AI in some capacity, yet innovation confidence averaged just 3 out of 5, and every respondent described their organization as only somewhat prepared to respond rapidly to industry change. A separate Trinity benchmark of new product planning and commercial strategy leaders found only 10 percent had a clear AI strategy they were scaling across workflows. Adoption is universal yet impact is not.

The reason is rarely the model. It is the distance between an insight and the moment someone acts on it. Targeting lists go stale between planning cycles. Omnichannel plans degrade. Next-best-action tools get ignored because reps cannot see why they should trust them. Brands pay twice, once for insight and again for a separate execution vendor, and still struggle to show impact. Closing that insight-to-action loop is the problem TrinityEDGE with Tovana will solve.

The acquisition also advances Trinity’s growth strategy. Over the past three years Trinity has augmented its advisory and insights services with the TrinityEDGE productized commercialization platform, adding software, data, and AI alongside 1,500 professionals in 14 offices on five continents. Verix deepens Trinity’s presence with the brand, field, and digital buyers who sit beyond its traditional strategy and insights relationships, and establishes a dedicated AI and product development center to build and ship commercial AI at scale.

Proof, not promise

Tovana is not a new build. It has been developed and validated in live pharmaceutical and biotech deployments since 2007, across large global pharma, mid-size biotech, and specialty and rare disease organizations.

Deployed at scale in oncology and specialty markets. Tovana supports commercial teams at global pharmaceutical companies and emerging biotechs, including publicly referenced work and support for the U.S. launch of a targeted oncology immunotherapy in a market its sponsor estimates at more than $400 million.

Measured commercial lift. One of the largest pharmaceutical oncology divisions in the United States increased leading KPIs, including new prescriptions, by 15 to 25 percent with Tovana. A rare oncology therapy team improved field-facing NPS by 12x.. A medical device commercial team improved sales outcomes within three months of implementation.

Time to value measured in weeks. Tovana’s pharma-specific data foundation, automated data pipelines, and pre-built model toolkit mean clients adopt targeting and engagement models already proven in live deployments, with rapid configuration and deployment inside a single planning cycle.

What clients get

A plan that holds up between quarters. Targeting, segmentation, and channel mix update against what the market is actually doing, so the engagement plan approved in January is still the plan operating in June.

Guidance the field will actually use. Recommendations arrive sourced and explainable, grounded in Trinity’s therapeutic, launch, and benchmarking depth, and delivered inside the field workflow through FieldAdvisor. That is the difference between a next-best-action a rep follows and one a rep ignores.

One partner instead of two. Existing Trinity clients get a path from insight they already own to execution, without standing up another vendor or rebuilding integrations. Existing Verix clients keep the product, roadmap, and support they rely on, and gain Trinity’s launch, market access, and competitive benchmarking context.

Tovana capabilities will be progressively integrated into the TrinityEDGE single sign-on environment over the coming months, strengthening CustomerEDGE™ execution, with the first joint offerings expected to reach clients in 1H 2027. Verix CEO Doron Aspitz joins Trinity’s leadership team and will continue to guide the Tovana roadmap.

Leadership perspective

“Every commercial leader I meet is asking how to put AI to work where it actually changes a call, a channel mix, or a forecast,” said Scott Evangelista, Chief Executive Officer of Trinity. “Insight has outpaced execution. Teams are rich in disparate analysis and thin in decisive action in front of a customer. Verix closes that gap. Next-best-action, dynamic targeting, and omnichannel orchestration now sit inside TrinityEDGE, proven in live pharma deployments and backed by 30 years of therapeutic and commercial judgment. That is what it means to lead in integrating human and artificial intelligence for life sciences commercialization.”

“We built Verix on one conviction: commercial teams deserve intelligence that is timely, explainable, and usable in the flow of work,” said Doron Aspitz, Chief Executive Officer of Verix. “Joining Trinity is the natural next step. Clients keep the product they rely on and gain the launch, access, and competitive context that tells them whether performance is genuinely competitive. I am proud of what our teams have built and energized by what we can now build together.”

About Verix

Verix is a leading provider of advanced commercial optimization solutions for the life sciences industry. Its flagship product, Tovana™, is a patented, AI-powered SaaS platform that enables life sciences companies to optimize commercial strategy and execution. Tovana integrates advanced machine learning, agentic workflows, and deep domain expertise into a single, intuitive platform, supporting dynamic targeting and segmentation, next best action, omnichannel orchestration, patient discovery, therapeutic landscape analysis, opportunity assessment, and bottom-up forecasting. Founded in 2007, Verix serves pharmaceutical, biotech, and specialty pharma commercial organizations from offices in the United States and Israel.

About Trinity

Trinity is a life sciences commercialization company that combines deep therapeutic, functional, and commercial expertise with AI-powered platforms. For more than 30 years, pharmaceutical, biotech, and medtech companies have relied on Trinity to connect strategy, data, and execution—supporting better decisions, more confident launches, and sustained commercial performance. Trinity helps clients turn insight into action and bring innovations to market with greater speed and confidence. Learn more at trinitylifesciences.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/trinity-acquires-verix-adding-ai-powered-next-best-action-and-omnichannel-orchestration-to-the-trinityedge-platform-302914278.html

SOURCE Trinity

Continue Reading

Technology

Baker Hill Launches $10,000 Battle of OKC Pitch Competition for Veteran Entrepreneurs

Published

on

By

New competition brings Baker Hill, The Verge OKC, IVMF, Gradient, and Oklahoma SBDC together to support Oklahoma veterans as they build and grow businesses

OKLAHOMA CITY, Oct. 20, 2026 /PRNewswire/ — Oklahoma veteran entrepreneurs will have the opportunity to compete for $10,000, showcase their businesses and connect with resources to help them grow through Battle of OKC, a new business pitch competition culminating live on Veterans Day in Oklahoma City.

Baker Hill today announced the competition in collaboration with The Verge OKC and the Institute for Veterans and Military Families (IVMF), Gradient and Oklahoma SBDC. Battle of OKC will bring veteran entrepreneurs together with business leaders, mentors and community resources while giving them a platform to put their ideas and businesses in the spotlight.

“Veterans know how to lead, adapt and find a way forward when the path isn’t obvious — the same qualities it takes to build a business,” said Andy Ivankovich, chairman and CEO of Baker Hill. “Battle of OKC is about putting opportunity behind that potential. We want to give veteran entrepreneurs a platform to tell their stories, connect with people and resources that can help them grow and compete for capital that can make a meaningful difference in what comes next.”

Battle of OKC is open Veteran entrepreneurs whose business is majority veteran-owned, has operated for at least one year, and is registered in Oklahoma. Applicants will begin by submitting a three-minute video introducing their business, the opportunity they see and why they are ready to take the next step. A panel will select 10 entrepreneurs to advance to finals.

Ten finalists will then advance to the live Battle of OKC on Veterans Day, Wednesday, Nov. 11, at the Verge in Oklahoma City, where they will pitch before a panel of judges and compete for a $10,000 grand prize.

The Verge OKC, a nonprofit community that helps turn ideas into impactful businesses, will help recruit and coach participating entrepreneurs throughout the competition.

“The Verge is all about connecting entrepreneurs with the people, resources, and opportunities they need to turn their ideas into thriving businesses”, said Kristin Garcia, Executive Director. “We’re excited to be part of Battle of OKC and to purposefully create space for our military community to engage with Oklahoma’s entrepreneurial ecosystem. Veterans bring valuable skills, leadership, and unique perspectives to business ownership, and they deserve to know there’s a community here ready to support them as they build and grow their businesses.”

The D’Aniello Institute for Veterans and Military Families (IVMF), will provide support outreach and recruitment/connect participating veterans with entrepreneurship resources/provide expertise.

“Just last month, we brought together veteran entrepreneurs, business leaders, and community partners in Oklahoma City for the Military Entrepreneurship Forum. Battle of OKC is a great example of how that momentum continues, with the community coming together to recognize, celebrate, and invest in Oklahoma’s veteran-owned businesses, said Barbara E. Carson, Managing Director, Programs and Policy. D’Aniello Institute for Veterans and Military Families. “At the D’Aniello IVMF, we know that when veteran entrepreneurs have access to the right networks, resources, and opportunities, they can build thriving businesses that strengthen their communities.”

Oklahoma SBDC will also provide recruitment and pitch coaching for the finalists the week of the event. “This collaboration brings together partners with complementary expertise to support Oklahoma’s veteran business owners,” said Dr. Michele Hockersmith, state director of the Oklahoma SBDC. “Our role is to help entrepreneurs connect their pitch to a sound business strategy, with clear financials and realistic growth plans. That preparation has value for the competition and beyond.”

Battle of OKC is designed to provide more than a stage and a prize. By bringing together veteran entrepreneurs, business leaders and organizations committed to supporting entrepreneurship, the competition creates connections and access to expertise that can continue well beyond the final pitch.

Veteran entrepreneurs interested in competing can learn more about eligibility and submit their three-minute video pitch at www.bakerhill.com/okc. Applications close October 29. Ten finalists will be selected to compete live in Oklahoma City on Veterans Day.

About Baker Hill
Baker Hill is the leading provider of commercial lending technology for banks and credit unions across the United States. Each month, financial institutions use Baker Hill’s platform to process more than $7 billion in lending originations — helping them Lend Better, Lend Faster, and Lend More™ in their communities. Backed by Flexpoint Ford, a private equity firm, Baker Hill delivers the scale, security and innovation required to meet the demands of modern banking. The company is headquartered in Carmel, Indiana, with operations in Santa Barbara, California. For more information, visit www.bakerhill.com.

About The Verge OKC
The Verge OKC, a 501(c)(3) nonprofit community that helps turn ideas into impactful businesses, will help recruit and coach participating entrepreneurs throughout the competition. Learn more: https://www.vergeokc.com 

About the D’Aniello Institute for Veterans and Military Families
The IVMF at Syracuse University is higher education’s first interdisciplinary academic institute, singularly focused on advancing the post-service lives of the nation’s military veterans and their families to serve those who have served. Learn more: https://ivmf.syracuse.edu 

About Oklahoma SBDC
The Oklahoma Small Business Development Center (Oklahoma SBDC) provides confidential, no-cost business advising, training and market research to help entrepreneurs start and grow businesses statewide. Hosted by Southeastern Oklahoma State University, the state-wide network helps business owners strengthen financial plans, prepare for financing and pursue growth opportunities. Learn more at www.oksbdc.org.

About Gradient
Gradient represents the blending of diverse ideas, people, and perspectives, adding texture and depth to our community. As one of the nation’s largest innovation hubs, Gradient fosters meaningful connections, nurtures bold ideas, and provides concierge introductions to entrepreneurial resources. Learn more at www.joingradient.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/baker-hill-launches-10-000-battle-of-okc-pitch-competition-for-veteran-entrepreneurs-302914275.html

SOURCE Baker Hill

Continue Reading

Trending